Polycystic Ovary Syndrome (PCOS) Treatment Market to Reach $4.6 Billion by 2027
Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 9. - Influencer Pool: 1173. - MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.
New York, March 31, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Polycystic Ovary Syndrome (PCOS) Treatment Industry" - https://www.reportlinker.com/p06042932/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
- Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.
Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.
Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.
Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.
Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.
Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.
Abstract:
- Global Polycystic Ovary Syndrome (PCOS) Treatment Market to Reach $4.6 Billion by 2027
- Amid the COVID-19 crisis, the global market for Polycystic Ovary Syndrome (PCOS) Treatment estimated at US$3.6 Billion in the year 2020, is projected to reach a revised size of US$4.6 Billion by 2027, growing at a CAGR of 3.5% over the analysis period 2020-2027. Oral Contraceptives, one of the segments analyzed in the report, is projected to record a 5% CAGR and reach US$1.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Antiandrogen segment is readjusted to a revised 3.7% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $981.1 Million, While China is Forecast to Grow at 6.4% CAGR
- The Polycystic Ovary Syndrome (PCOS) Treatment market in the U.S. is estimated at US$981.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$983.7 Million by the year 2027 trailing a CAGR of 6.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1% and 2.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.
- Insulin-Sensitizing Agents Segment to Record 3.1% CAGR
- In the global Insulin-Sensitizing Agents segment, USA, Canada, Japan, China and Europe will drive the 2.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$924 Million in the year 2020 will reach a projected size of US$1.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$646 Million by the year 2027, while Latin America will expand at a 3.9% CAGR through the analysis period.
- Select Competitors (Total 42 Featured) -
Addex Therapeutics
AstraZeneca PLC
Bristol-Myers Squibb Company
Crinetics Pharmaceuticals, Inc.
Ferring Pharmaceuticals, Inc.
JSC BIOCAD
Merck KgaA
Teva Pharmaceutical Industries Ltd.
Read the full report: https://www.reportlinker.com/p06042932/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2020 & 2027
Table 4: World Current & Future Analysis for Oral
Contraceptives by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR
Table 5: World Historic Review for Oral Contraceptives by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 6: World 15-Year Perspective for Oral Contraceptives by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 7: World Current & Future Analysis for Antiandrogen by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 8: World Historic Review for Antiandrogen by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 9: World 15-Year Perspective for Antiandrogen by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 10: World Current & Future Analysis for
Insulin-Sensitizing Agents by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR
Table 11: World Historic Review for Insulin-Sensitizing Agents
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 12: World 15-Year Perspective for Insulin-Sensitizing
Agents by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027
Table 13: World Current & Future Analysis for Antidepressants
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 14: World Historic Review for Antidepressants by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 15: World 15-Year Perspective for Antidepressants by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 16: World Current & Future Analysis for Anti-Obesity
Agents by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 17: World Historic Review for Anti-Obesity Agents by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 18: World 15-Year Perspective for Anti-Obesity Agents by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 19: World Current & Future Analysis for Ovarian Wedge
Resection by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 20: World Historic Review for Ovarian Wedge Resection by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 21: World 15-Year Perspective for Ovarian Wedge Resection
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 22: World Current & Future Analysis for Laparoscopic
Ovarian Drilling by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR
Table 23: World Historic Review for Laparoscopic Ovarian
Drilling by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR
Table 24: World 15-Year Perspective for Laparoscopic Ovarian
Drilling by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027
III. MARKET ANALYSIS
UNITED STATES
Table 25: USA Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 26: USA Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 27: USA 15-Year Perspective for Polycystic Ovary Syndrome
(PCOS) Treatment by Drug Class - Percentage Breakdown of Value
Sales for Oral Contraceptives, Antiandrogen,
Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity
Agents for the Years 2012, 2020 & 2027
Table 28: USA Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge
Resection and Laparoscopic Ovarian Drilling - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 29: USA Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 30: USA 15-Year Perspective for Polycystic Ovary Syndrome
(PCOS) Treatment by Surgery Type - Percentage Breakdown of
Value Sales for Ovarian Wedge Resection and Laparoscopic
Ovarian Drilling for the Years 2012, 2020 & 2027
CANADA
Table 31: Canada Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 32: Canada Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 33: Canada 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown
of Value Sales for Oral Contraceptives, Antiandrogen,
Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity
Agents for the Years 2012, 2020 & 2027
Table 34: Canada Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge
Resection and Laparoscopic Ovarian Drilling - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 35: Canada Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 36: Canada 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Percentage
Breakdown of Value Sales for Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
JAPAN
Table 37: Japan Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 38: Japan Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 39: Japan 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown
of Value Sales for Oral Contraceptives, Antiandrogen,
Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity
Agents for the Years 2012, 2020 & 2027
Table 40: Japan Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge
Resection and Laparoscopic Ovarian Drilling - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 41: Japan Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 42: Japan 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Percentage
Breakdown of Value Sales for Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
CHINA
Table 43: China Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 44: China Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 45: China 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown
of Value Sales for Oral Contraceptives, Antiandrogen,
Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity
Agents for the Years 2012, 2020 & 2027
Table 46: China Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge
Resection and Laparoscopic Ovarian Drilling - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 47: China Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 48: China 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Percentage
Breakdown of Value Sales for Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
EUROPE
Table 49: Europe Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 50: Europe Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Geographic Region - France, Germany, Italy,
UK, Spain, Russia and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 51: Europe 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
Table 52: Europe Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 53: Europe Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 54: Europe 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown
of Value Sales for Oral Contraceptives, Antiandrogen,
Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity
Agents for the Years 2012, 2020 & 2027
Table 55: Europe Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge
Resection and Laparoscopic Ovarian Drilling - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 56: Europe Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 57: Europe 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Percentage
Breakdown of Value Sales for Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
FRANCE
Table 58: France Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 59: France Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 60: France 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown
of Value Sales for Oral Contraceptives, Antiandrogen,
Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity
Agents for the Years 2012, 2020 & 2027
Table 61: France Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge
Resection and Laparoscopic Ovarian Drilling - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 62: France Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 63: France 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Percentage
Breakdown of Value Sales for Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
GERMANY
Table 64: Germany Current & Future Analysis for Polycystic
Ovary Syndrome (PCOS) Treatment by Drug Class - Oral
Contraceptives, Antiandrogen, Insulin-Sensitizing Agents,
Antidepressants and Anti-Obesity Agents - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR
Table 65: Germany Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 66: Germany 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown
of Value Sales for Oral Contraceptives, Antiandrogen,
Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity
Agents for the Years 2012, 2020 & 2027
Table 67: Germany Current & Future Analysis for Polycystic
Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge
Resection and Laparoscopic Ovarian Drilling - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 68: Germany Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 69: Germany 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Percentage
Breakdown of Value Sales for Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
ITALY
Table 70: Italy Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 71: Italy Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 72: Italy 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown
of Value Sales for Oral Contraceptives, Antiandrogen,
Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity
Agents for the Years 2012, 2020 & 2027
Table 73: Italy Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge
Resection and Laparoscopic Ovarian Drilling - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 74: Italy Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 75: Italy 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Percentage
Breakdown of Value Sales for Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
UNITED KINGDOM
Table 76: UK Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 77: UK Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 78: UK 15-Year Perspective for Polycystic Ovary Syndrome
(PCOS) Treatment by Drug Class - Percentage Breakdown of Value
Sales for Oral Contraceptives, Antiandrogen,
Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity
Agents for the Years 2012, 2020 & 2027
Table 79: UK Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge
Resection and Laparoscopic Ovarian Drilling - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 80: UK Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 81: UK 15-Year Perspective for Polycystic Ovary Syndrome
(PCOS) Treatment by Surgery Type - Percentage Breakdown of
Value Sales for Ovarian Wedge Resection and Laparoscopic
Ovarian Drilling for the Years 2012, 2020 & 2027
SPAIN
Table 82: Spain Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 83: Spain Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 84: Spain 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown
of Value Sales for Oral Contraceptives, Antiandrogen,
Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity
Agents for the Years 2012, 2020 & 2027
Table 85: Spain Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge
Resection and Laparoscopic Ovarian Drilling - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 86: Spain Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 87: Spain 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Percentage
Breakdown of Value Sales for Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
RUSSIA
Table 88: Russia Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 89: Russia Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 90: Russia 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown
of Value Sales for Oral Contraceptives, Antiandrogen,
Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity
Agents for the Years 2012, 2020 & 2027
Table 91: Russia Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge
Resection and Laparoscopic Ovarian Drilling - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 92: Russia Historic Review for Polycystic Ovary Syndrome
(PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 93: Russia 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Percentage
Breakdown of Value Sales for Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
REST OF EUROPE
Table 94: Rest of Europe Current & Future Analysis for
Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral
Contraceptives, Antiandrogen, Insulin-Sensitizing Agents,
Antidepressants and Anti-Obesity Agents - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR
Table 95: Rest of Europe Historic Review for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 96: Rest of Europe 15-Year Perspective for Polycystic
Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage
Breakdown of Value Sales for Oral Contraceptives, Antiandrogen,
Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity
Agents for the Years 2012, 2020 & 2027
Table 97: Rest of Europe Current & Future Analysis for
Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type -
Ovarian Wedge Resection and Laparoscopic Ovarian Drilling -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 98: Rest of Europe Historic Review for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge
Resection and Laparoscopic Ovarian Drilling Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 99: Rest of Europe 15-Year Perspective for Polycystic
Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage
Breakdown of Value Sales for Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Table 100: Asia-Pacific Current & Future Analysis for
Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region -
Australia, India, South Korea and Rest of Asia-Pacific
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 101: Asia-Pacific Historic Review for Polycystic Ovary
Syndrome (PCOS) Treatment by Geographic Region - Australia,
India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 102: Asia-Pacific 15-Year Perspective for Polycystic
Ovary Syndrome (PCOS) Treatment by Geographic Region -
Percentage Breakdown of Value Sales for Australia, India, South
Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 &
2027
Table 103: Asia-Pacific Current & Future Analysis for
Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral
Contraceptives, Antiandrogen, Insulin-Sensitizing Agents,
Antidepressants and Anti-Obesity Agents - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR
Table 104: Asia-Pacific Historic Review for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 105: Asia-Pacific 15-Year Perspective for Polycystic
Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage
Breakdown of Value Sales for Oral Contraceptives, Antiandrogen,
Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity
Agents for the Years 2012, 2020 & 2027
Table 106: Asia-Pacific Current & Future Analysis for
Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type -
Ovarian Wedge Resection and Laparoscopic Ovarian Drilling -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 107: Asia-Pacific Historic Review for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge
Resection and Laparoscopic Ovarian Drilling Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 108: Asia-Pacific 15-Year Perspective for Polycystic
Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage
Breakdown of Value Sales for Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
AUSTRALIA
Table 109: Australia Current & Future Analysis for Polycystic
Ovary Syndrome (PCOS) Treatment by Drug Class - Oral
Contraceptives, Antiandrogen, Insulin-Sensitizing Agents,
Antidepressants and Anti-Obesity Agents - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR
Table 110: Australia Historic Review for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 111: Australia 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown
of Value Sales for Oral Contraceptives, Antiandrogen,
Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity
Agents for the Years 2012, 2020 & 2027
Table 112: Australia Current & Future Analysis for Polycystic
Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge
Resection and Laparoscopic Ovarian Drilling - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 113: Australia Historic Review for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge
Resection and Laparoscopic Ovarian Drilling Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 114: Australia 15-Year Perspective for Polycystic Ovary
Syndrome (PCOS) Treatment by Surgery Type - Percentage
Breakdown of Value Sales for Ovarian Wedge Resection and
Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
INDIA
Table 115: India Current & Future Analysis for Polycystic Ovary
Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives,
Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and
Anti-Obesity Agents - Independent Analysis of Annual Sales in
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06042932/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001